1
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Compositions and methods for binding sphingosine-1-phosphate. Lpath, BioTechnology Law Group, Daniel M Chambers, November 9, 2010: US07829674 (4 worldwide citation)

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.


2
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Williams: Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, September 27, 2011: US08025877 (2 worldwide citation)

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...


3
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Compositions and methods for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, September 27, 2011: US08026342 (1 worldwide citation)

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.


4

5
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Humanized antibodies and compositions for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, July 17, 2012: US08222373

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...


6
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Nucleic acids coding for humanized antibodies for binding sphingosine-1-phosphate. Lpath, Daniel M Chambers, BioTechnology Law Group, June 7, 2011: US07956173

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...


7
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Humanized antibodies and compositions for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, November 29, 2011: US08067549

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...


8
Nagendu B Dev, Sukhendu B Dev, Gunter A Hofmann: Electrically induced vessel vasodilation. Genetronics, Daniel M Chambers, Douglas C Murdock, BioTechnology Law Group, March 8, 2005: US06865416 (196 worldwide citation)

The invention provides methods for inducing or increasing the vasodilation of a vessel. The invention further provides methods for inducing or increasing the flow of fluid through a vessel. An electrical impulse is applied to the vessel in order to induce or increase vessel vasodilation or to induce ...


9
Lei Zhang, Dietmar P Rabussay: Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation. Genetronics, Daniel M Chambers, Douglas C Murdock, Bio Technology Law Group, December 6, 2005: US06972013 (111 worldwide citation)

In vivo methods are provided for using an electric field to delivery therapeutic or immunizing treatment to a subject by applying non-invasive, user-friendly electrodes to the surface of the skin. Thus, therapeutic or immunizing agents can be delivered into cells of skin for local and systemic treat ...


10
Suk Zu Song, Andrew Morawiecki: Collagen-containing sponges as drug delivery compositions for proteins. Amgen, Daniel M Chambers, Daniel R Curry, March 21, 1995: US05399361 (108 worldwide citation)

Collagen-containing sponges comprising an absorbable gelatin sponge, collagen, and an active ingredient are disclosed as are methods of enhancing wound healing of external and internal wounds using such sponges.